Form 4: Fennec Director Raykov Reports Stock Transactions

Fennec Pharmaceuticals Director Rosty Raykov reported the acquisition of shares from restricted stock and option exercise, alongside a sale to cover tax obligations, all under a pre-arranged 10b5-1 plan.

Summary

• Rosty Raykov, a Director of Fennec Pharmaceuticals Inc. (FENC), reported multiple transactions involving the company's common shares.
• Acquired 5,208 common shares on December 31, 2025, which were released from restriction from awards made on March 31, 2023, and May 16, 2024, at a price of $0 per share.
• Exercised 15,598 stock options on January 2, 2026, at an exercise price of $2.45 per share, resulting in the acquisition of 15,598 common shares.
• Sold 10,312 common shares on January 2, 2026, at a price of $7.6 per share, specifically to satisfy tax obligations related to the option exercise.
• All reported transactions were conducted pursuant to a Rule 10b5-1 plan adopted on September 19, 2025.
• Following these transactions, direct beneficial ownership of common shares increased to 88,020.
• The reporting person continues to beneficially own 1,618,586 stock options with an exercise price of $2.45, exercisable from July 5, 2016, and expiring on July 5, 2026.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. While there was a sale of shares, it was explicitly for tax obligations related to an option exercise, which is a common and expected event for executives. The overall beneficial ownership of common shares increased, and the transactions were pre-planned under a 10b5-1 plan, reducing any negative inference from the sale.

Positives

• A Director acquired 5,208 common shares through the release of restricted stock, indicating vesting of previously granted equity awards.
• A Director exercised 15,598 stock options, converting them into common shares, which increases their direct equity stake in the company (prior to the tax-related sale).

Negatives

• A Director sold 10,312 common shares to cover tax obligations arising from the option exercise, reducing their net increase in direct beneficial ownership.

Future Outlook

This Form 4 filing details past and planned insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction report is specific to Fennec Pharmaceuticals and its director's equity holdings. It does not provide information directly related to broader industry trends or competitive landscape, as it focuses solely on individual stock ownership changes.

Stakeholder Impact

• Shareholders: The increase in a director's direct beneficial ownership, even with a tax-related sale, can be viewed as a minor positive signal of management's continued alignment with shareholder interests. The pre-planned nature of the transactions under a 10b5-1 plan ensures transparency and reduces concerns about opportunistic trading.

Key Dates

Recommendation

The Form 4 filing details routine insider transactions by a director, including the exercise of options and the sale of shares to cover tax obligations, all executed under a pre-arranged 10b5-1 plan. While the director increased their overall direct beneficial ownership, these transactions are largely administrative and do not provide new fundamental information to warrant a change in investment recommendation based solely on this filing. A 'hold' recommendation is appropriate as this filing does not present new material information to alter the existing investment thesis.

Keywords

Fennec Pharmaceuticals, FENC, Form 4, Insider Transaction, Director, Stock Options, Restricted Stock, 10b5-1 Plan, Share Acquisition, Share Disposition, Equity Compensation